Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

These funds could help you build wealth over the long term. The post How to build wealth with ASX ETFs appeared first on The ...

Mumbai, Delhi and Bengaluru alone account for one-third of GLP-1 sales. Analysts cite affordability, accessibility and ...

Pfizer deals again in obesity space as Wave and Structure drop splashy weight loss results; what CDER Director Richard Pazdur ...

December 2025 US stock market outlook key takeaways. US stock market trading at 3% discount to the composite of our ...

Novo Nordisk remains a Strong Buy despite recent earnings misses, trial setbacks, and competitive pressures in the weight loss/diabetes market. NVO's valuation is compelling, trading at a low P/E of ...

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease. Novo ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

A Novo Nordisk challenge has driven a Pennsylvania-based telehealth company to voluntarily discontinue compounded semaglutide product claims, adding to the Danish drugmaker’s string of wins against ...

Novo Nordisk announced Monday it is lowering costs for weight loss and diabetes drugs, weeks after it struck a deal with the Trump administration to drop prices for customers. The Wegovy 0.25 ...

GLP-1 weight loss drugs are still far from cheap, but some of the prices keep dropping. Novo Nordisk is now offering people who pay out of pocket a steep discount for select doses of Ozempic and ...